GREENVILLE, S.C.--(BUSINESS WIRE)--Kiyatec, leaders in functional precision oncology, today announced the publication of a pivotal study in Scientific Reports highlighting the impact of the 3D Predict ...

Chimerix, Inc. (CMRX) announced that the FDA had accepted for review its New Drug Application [NDA] of dordaviprone for the treatment of patients with recurrent H3 K27M-mutant diffuse glioma. Not only ...

Pediatric gliomas are also known as childhood gliomas. They’re a type of tumor that can develop in a child’s central nervous system (CNS), including their brain or spinal cord. Gliomas are tumors that ...

Fractionated reirradiation is safe for recurrent high-grade glioma, with a median dose of 41.4 Gy and no critical structure injuries observed. Improved overall survival correlates with better ...

Pediatric high-grade gliomas, particularly H3K27M diffuse midline gliomas (DMG), are aggressive malignant brain tumors with a poor prognosis. Previous research suggests that platelet-derived growth ...

Pediatric high-grade gliomas, particularly H3K27M diffuse midline gliomas (DMG), are aggressive malignant brain tumors with a poor prognosis. Previous research suggests that platelet-derived growth ...

High-grade glioma, an aggressive form of pediatric and adult brain cancer, is challenging to treat given the tumor location, incidence of recurrence and difficulty for drugs to cross the blood-brain ...

Iopofosine-131 received rare pediatric drug designation for treating relapsed or refractory pediatric high-grade glioma, highlighting its potential in addressing aggressive pediatric brain cancers.

Uncertainty persists about the value of palliative radiation, particularly longer regimens, among patients with high-grade gliomas. To address the uncertainty, investigators administered quality of ...